Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia.
Ng SWK, Murphy T, King I, Zhang T, Mah M, Lu Z, Stickle N, Ibrahimova N, Arruda A, Mitchell A, Mai M, He R, Madala BS, Viswanatha DS, Dick JE, Chan S, Virtanen C, Minden MD, Mercer T, Stockley T, Wang JCY. Ng SWK, et al. Among authors: chan s. Blood Adv. 2022 Feb 8;6(3):1064-1073. doi: 10.1182/bloodadvances.2021005741. Blood Adv. 2022. PMID: 34872104 Free PMC article.
Biological and clinical consequences of NPM1 mutations in AML.
Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD. Heath EM, et al. Among authors: chan sm. Leukemia. 2017 Apr;31(4):798-807. doi: 10.1038/leu.2017.30. Epub 2017 Jan 23. Leukemia. 2017. PMID: 28111462 Review.
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
Farshchi Zarabi S, Chan S, Gupta V, Khalaf D, Lutynski A, Minden MD, Rostom A, Rydlewski A, Schuh AC, Sibai H, Yee KWL, Schimmer AD. Farshchi Zarabi S, et al. Among authors: chan s. Leuk Lymphoma. 2018 Jan;59(1):237-240. doi: 10.1080/10428194.2017.1323273. Epub 2017 Jun 9. Leuk Lymphoma. 2018. PMID: 28595467 No abstract available.
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Kavanagh S, Heath E, Hurren R, Gronda M, Barghout SH, Liyanage SU, Siriwardena TP, Claudio J, Zhang T, Sukhai M, Stockley TL, Kamel-Reid S, Rostom A, Lutynski A, Khalaf D, Rydlewski A, Chan SM, Gupta V, Maze D, Sibai H, Schuh AC, Yee K, Minden MD, Schimmer AD. Kavanagh S, et al. Among authors: chan sm. Leuk Res. 2018 May;68:22-28. doi: 10.1016/j.leukres.2018.02.012. Epub 2018 Feb 20. Leuk Res. 2018. PMID: 29518628
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V. McNamara CJ, et al. Among authors: chan s. Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469. Blood Adv. 2018. PMID: 30327374 Free PMC article.
The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.
Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD. Seneviratne AK, et al. Among authors: chan s. Cell Stem Cell. 2019 Apr 4;24(4):621-636.e16. doi: 10.1016/j.stem.2019.02.020. Epub 2019 Mar 28. Cell Stem Cell. 2019. PMID: 30930145 Free PMC article.
9,542 results